Colliers International expands Project Management in Australia
Acquisition strengthens services to property owners and developers
SYDNEY, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Leading global commercial real estate firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) today announced the acquisition of NixAnderson, an Australian project management firm with extensive experience in corporate property and infrastructure delivery services. Since 1999, NixAnderson has been providing world class project management and planning services across Australia and New Zealand. These services include project management, program management, property acquisition services, workspace consulting, and feasibility studies, to a broad range of industry verticals, including social infrastructure, defence, healthcare, hospitality, retail, and commercial. NixAnderson has over 30 professionals with a combined industry experience of over 200 years. The acquisition more than doubles the number of Colliers project management professionals in the Australia and New Zealand business. The terms of the transaction were not disclosed.
"We are very excited to become part of Colliers International," said Derek Nix and Scott Anderson. "Combining our expertise in corporate property and infrastructure delivery services with the Colliers International platform, both in Australia and globally, enhances our ability to provide industry leading service to existing and new clients. Further, there is an extremely strong alignment with the entrepreneurial spirit that exists throughout Colliers. We are excited to join this world class, growing organization."
"The acquisition of NixAnderson builds on our reputation for delivering complex projects and positions Colliers International for even greater growth in the region," said John Kenny, Chief Executive Officer, Australia and New Zealand. "Our new and expanded project management capability is well positioned to capitalise on the unprecedented level of capital investment in Australia and New Zealand's commercial, residential and public infrastructure market segments."
"What attracted us to NixAnderson was the combination of their strong cultural fit with Colliers International and their proven track of providing excellent project management services," said Dylan Taylor, President & Chief Operating Officer. "By bringing in Derek and Scott and their team of industry-leading project management professionals, each of whom share the enterprising culture of Colliers, we are delivering on our promise to accelerate the success of our clients."
About Colliers International
Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is an industry leading global real estate services company with 15,000 skilled professionals operating in 68 countries. With an enterprising culture and significant employee ownership, Colliers professionals provide a full range of services to real estate occupiers, owners and investors worldwide. Services include strategic advice and execution for property sales, leasing and finance; global corporate solutions; property, facility and project management; workplace solutions; appraisal, valuation and tax consulting; customized research; and thought leadership consulting.
Colliers professionals think differently, share great ideas and offer thoughtful and innovative advice that helps clients accelerate their success. Colliers has been ranked among the top 100 global outsourcing firms by the International Association of Outsourcing Professionals for 12 consecutive years, more than any other real estate services firm. Colliers also has been ranked the top property manager in the world by Commercial Property Executive for two years in a row.
Advisory Regarding Forward-Looking Information
Certain information included in this news release is forward-looking, within the meaning of applicable securities laws. Much of this information can be identified by words such as "believe", "expects", "expected", "will", "intends", "projects", "anticipates", "estimates", "continues" or similar expressions suggesting future outcomes or events. Colliers believes the expectations reflected in such forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon.
Forward-looking statements are based on current information and expectations that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those anticipated. These risks include, but are not limited to, risks associated with: (i) general economic and business conditions, which will, among other things, impact demand for Colliers' services and the cost of providing services; (ii) the ability of Colliers to implement its business strategy, including Colliers' ability to identify and acquire suitable acquisition candidates on acceptable terms and successfully integrate newly acquired businesses with its existing businesses; (iii) changes in or the failure to comply with government regulations; and (iv) such factors as are identified in the Annual Information Form of Colliers for the year ended December 31, 2016 under the heading "Risk Factors" (which factors are adopted herein and a copy of which can be obtained at www.sedar.com). Forward looking statements contained in this news release are made as of the date hereof and are subject to change. All forward-looking statements in this news release are qualified by these cautionary statements. Except as required by applicable law, Colliers undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
John B. Friedrichsen
Chief Financial Officer
Phone: (416) 960-9500
Chief Executive Officer | Australia & New Zealand
Phone: +61 2 9257 0212
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Colliers International Group Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum